Added: Oct 14, 2008
From: MedPageToday
Duration: 4:47
Elliott M. Antman, M.D., Brigham and Women's Hospitalhttp://www.medpagetoday.comORLANDO, Nov. 4 -- Prasugrel, a super-potent investigational antiplatelet agent, significantly reduced myocardial infarction, urgent target vessel revascularization, and stent thrombosis compared with clopidogrel (Plavix), researchers reported here today.
Channel: Education
Tags: health infarction medicine myocardial plavix prasugrel revascularization
Rating: 5.00 (1 ratings) Views: 248' favoriteCount='1 Comments: 0